|
WO2021043345A1
|
|
Human recombinant hyposialylated erythropoietin, methods of purification and therapeutic uses thereof
|
|
CU20180039A7
|
|
FUSION PROTEINS COMPOSED OF INTERLEUKIN 2 MUTEIN AND TYPE 1 INTERFERON
|
|
AU2018234783A1
|
|
Method for the treatment of patients with carcinomas
|
|
US2020011870A1
|
|
Method for the treatment of patients with carcinomas
|
|
CU20170173A7
|
|
NANO-PARTICLES CONTAINING GM3 GANGLIOSIDE AS IMMUNOMODULATORS
|
|
CU20170148A7
|
|
AFFINITY ANTIBODIES INCREASED BY THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND ITS DERIVED FRAGMENTS
|
|
CU20170137A7
|
|
NANO-PARTICLES CONTAINING SYNTHETIC VARIANTS OF GM3 GANGLIOSIDE AS ADJUVANTS IN VACCINES
|
|
WO2017220053A1
|
|
Use of the basic form of recombinant human erythropoietin in the treatment of patients with spinocerebellar ataxia with cag repeat mutations
|
|
CU20160171A7
|
|
METHOD FOR INCREASING INTERLEUKIN-2 SECRETION LEVELS
|
|
JP2016153435A
|
|
Pharmaceutical compositions for treatment of tumors expressing egfr and gm3 n-glycolyl ganglioside (neugcgm3)
|
|
CN105407916A
|
|
Divalent vaccine compositions and the use thereof for treating tumours
|
|
UA115678C2
|
|
POLYPEPTIDES DERIVED FROM TGFβ AND USES THEREOF
|
|
CN101970493A
|
|
A monoclonal antibody and a method thereof
|
|
JO3599B1
|
|
Pharmaceutical composition comprising an anti- cd6 monoclonal antibody useful for the diagnosis and treatment of rheumatoid arthritis
|
|
AU2007336564A1
|
|
Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-Chronic Lymphocytic Leukaemia
|
|
AU2007336563A1
|
|
Pharmaceutical composition, comprising an anti-CD6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
|
|
AU2007203242A1
|
|
Vaccine composition containing transforming growth factor alpha
|
